Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from the Serum Institute of India

Meet the ultra-rich Indians shaking up London's art scene

It’s boom time for Indian art: the market is at an all-time high, while London has had a slew of exhibitions focused on South Asian artists, supported by a new class of megadonors

Evening Standard

How is new malaria vaccine drive working in West Africa?

How does the new R21/Matrix-M vaccine work and where is it being administered?

Al Jazeera

Covishield side effects | Doctors’ group urges Centre to review all COVID vaccines

Doctors express concern over Covishield vaccine safety due to potential blood clot side effects, urging government review and action.

The Hindu

From analysis to the latest developments in health,
read the most diverse news in one place.

Covishield manufacture stopped since December 2021; have disclosed all side effects in packaging: Serum Institute of India

Amidst huge uproar regarding the side effect of Covishield, the Serum Institute of India has said that it has stopped the manufacture and supply of additional doses of Covishield from December 2021 and this was done in view of the significantly decreasing demand for previous vaccines.

The Times of India

Two new malaria vaccines are being rolled out across Africa — how they work and what they promise

Malaria incidents are on the rise. There were 249 million cases of this parasitic disease in 2022, five million more than in 2021.

The Hindu

Why is the R21/Matrix malaria vaccine being called ‘revolutionary’? | Explained

The R21/Matrix malaria vaccine is 75% effective in reducing episodes over a year, can be manufactured at scale, and is cost-effective. It has the potential to reduce the burden of malaria in Africa and beyond.

The Hindu

'We could eradicate malaria by 2040' says expert after revolutionary vaccine is approved by WHO

The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year. Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

The long road to a new malaria vaccine, told by the scientists behind the breakthrough – podcast

The world has waited decades for a malaria vaccine, and now two have come along in quick succession. On October 2, the World Health Organization (WHO) recommended that a new malaria vaccine, R21, developed by the University of Oxford be rolled out for the prevention of malaria in children, just…

The Conversation

WHO recommends Malaria vaccine made by Oxford University and Serum Institute of India

To date, the R21/Matrix-M malaria vaccine has been licensed for use in Ghana, Nigeria and Burkina Faso. Read further on Dynamite News

Dynamite News

Oxford-Serum institute malaria vaccine recommended for use by WHO

WHO recommends R21/Matrix-M malaria vaccine developed by Oxford and Serum Institute of India. Vaccine has met safety, quality and effectiveness standards. Serum Institute has established production capacity for 100 million doses/annum. Vaccine efficacy over 12 months is 75% at sites with high seasonal malaria transmission and 68% at sites with…

The Hindu

Oxford malaria vaccine wins first approval from Ghana in ‘significant milestone’

600,000 die every year from the disease, mostly children in Africa

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

the University of Oxford

146 stories

Reliance Industries

132 stories

The Conversation Weekly

Serum Institute of India

23 stories

SII

22 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.